Committed to Making a Difference in the Lives of Patients with Rare Diseases

Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company. We are advancing a pipeline of endocrinology programs focused on making a difference in patients’ lives. By utilizing our TransCon technology with clinically validated parent drugs, we create new therapies with potential for best-in-class efficacy, safety and/or convenience.

Late-stage TransCon Growth Hormone

TransCon Growth Hormone is being evaluated as a once-weekly therapy for children with growth hormone deficiency. The phase 3 heiGHt Trial compares TransCon Growth Hormone administered once-weekly to a daily growth hormone treatment. The heiGHt Trial has completed enrollment and top-line results are expected in the first quarter of 2019.

Proprietary Technology Platform

Our TransCon technology creates a prodrug designed to slowly release the unmodified parent drug.  The parent drug is transiently bound to the inert TransCon carrier via a TransCon linker.  Through autohydrolysis, the parent drug is subsequently released, and the carrier and linker are eliminated by renal clearance. Read More